Sunesis Pharmaceuticals (SNSS) Sees Continued Upside Momentum
Tweet
Share
E-mailGet Alerts SNSS Hot Sheet
Join SI Premium – FREE
Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS) is on the move again. Shares are up 35% today after rising 131% yesterday. Volume is surging.
After the close Monday, the company announced positive data from two Phase 2 clinical trials of the Company's lead drug candidate, voreloxin.
The results highlight voreloxin's strong efficacy and safety profile when used as a single agent or in combination with chemotherapy in patients with difficult to treat acute myeloid leukemia.
The stock has been up everyday since. Shares were up 20% on 12/8 and another 13% on 12/9 and 131% on 12/10.
After the close Monday, the company announced positive data from two Phase 2 clinical trials of the Company's lead drug candidate, voreloxin.
The results highlight voreloxin's strong efficacy and safety profile when used as a single agent or in combination with chemotherapy in patients with difficult to treat acute myeloid leukemia.
The stock has been up everyday since. Shares were up 20% on 12/8 and another 13% on 12/9 and 131% on 12/10.
You May Also Be Interested In
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
